PMID- 38313307
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240206
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 15
DP  - 2024
TI  - Denosumab, teriparatide and bisphosphonates for glucocorticoid-induced 
      osteoporosis: a Bayesian network meta-analysis.
PG  - 1336075
LID - 10.3389/fphar.2024.1336075 [doi]
LID - 1336075
AB  - Background: Several medications have been used for glucocorticoids-induced 
      osteoporosis (GIO). However, the best therapeutic option for GIO is still 
      controversial. A Bayesian network meta-analysis was conducted to compare the 
      efficacy and safety of denosumab, teriparatide and bisphosphonates for patients 
      with GIO. Methods: Relevant randomized controlled trials published in PubMed, 
      Embase, Cochrane Library and ClinicalTrials.gov up to August 2023 were searched. 
      The following efficiency and safety outcomes were extracted for comparison: bone 
      mineral density (BMD) percentage changes in lumbar spine, femur neck and total 
      hip, and incidences of adverse events (AEs), serious adverse events (SAEs), 
      vertebrae and non-vertebrae fracture. Bayesian random effects models were used 
      for multiple treatment comparisons. Results: 11 eligible RCTs involving 2,877 
      patients were identified. All the six medications including alendronate, 
      risedronate, etidronate, zoledronate, teriparatide, and denosumab and were 
      effective in increasing BMD. Teriparatide and denosumab were more effective in 
      improving lumbar spine and femur neck BMD, and reducing vertebrae fracture. 
      Alendronate and denosumab were more effective in improving total hip BMD. 
      Alendronate and teriparatide had the lowest incidences of AEs and SAEs. 
      Conclusion: Teriparatide denosumab and the bisphosphonates are all effective in 
      improving BMD for GIO patients. Based on this network meta-analysis, teriparatide 
      and denosumab have higher efficiency in improving lumbar spine and femur neck 
      BMD, and reducing vertebrae fracture. Systematic Review Registration: 
      10.17605/OSF.IO/2G8YA, identifier CRD42023456305.
CI  - Copyright (c) 2024 Dong, Jiang, Xu and Zhang.
FAU - Dong, Liang
AU  - Dong L
AD  - Department of Orthopedic, Hong-Hui Hospital, Xi'an Jiaotong University College of 
      Medicine, Xi'an, China.
FAU - Jiang, Lianghai
AU  - Jiang L
AD  - Department of Spinal Surgery, Qingdao Hospital, University of Health and 
      Rehabilitation Sciences (Qingdao Municipal Hospital), Qingdao, China.
FAU - Xu, Zhengwei
AU  - Xu Z
AD  - Department of Orthopedic, Hong-Hui Hospital, Xi'an Jiaotong University College of 
      Medicine, Xi'an, China.
FAU - Zhang, Xiaobo
AU  - Zhang X
AD  - Department of Orthopedic, Hong-Hui Hospital, Xi'an Jiaotong University College of 
      Medicine, Xi'an, China.
LA  - eng
PT  - Systematic Review
DEP - 20240119
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC10834754
OTO - NOTNLM
OT  - bone mineral density
OT  - fracture
OT  - glucocorticoids
OT  - network meta-analysis
OT  - osteoporosis
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2024/02/05 06:43
MHDA- 2024/02/05 06:44
PMCR- 2024/01/19
CRDT- 2024/02/05 04:38
PHST- 2023/11/10 00:00 [received]
PHST- 2024/01/10 00:00 [accepted]
PHST- 2024/02/05 06:44 [medline]
PHST- 2024/02/05 06:43 [pubmed]
PHST- 2024/02/05 04:38 [entrez]
PHST- 2024/01/19 00:00 [pmc-release]
AID - 1336075 [pii]
AID - 10.3389/fphar.2024.1336075 [doi]
PST - epublish
SO  - Front Pharmacol. 2024 Jan 19;15:1336075. doi: 10.3389/fphar.2024.1336075. 
      eCollection 2024.